8. Conclusion
The PARAGEN collection represents a significant advance in the strategic exploitation of bacteriocins, opening up innovative avenues to meet the challenges of the "One Health" approach. Research devoted to these peptides in the treatment of bacterial infections reveals considerable therapeutic potential, underlined by their ability to precisely target pathogens, while preserving the beneficial microbiome. What's more, the promising alliance between synthetic biology and artificial intelligence marks the threshold of an imminent revolution in the discovery and optimization of new bacteriocins, accelerating their application and integration in various sectors. Despite existing challenges, the outlook for bacteriocins is exceptionally promising, carrying with it as yet untapped potential.
Thanks
We would...
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference
This article is included in
Bioprocesses and bioproductions
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Conclusion
Bibliography
Patents
Controlled growth of microorganisms. US Patent 9,333,227 / 10,188,114 + CN Patent ZL 201480057387.2 + EP3035802B1 + BR1120160035330 + IN389267
Engineering bacteriocins. US Patent Application 62681529 (filed June 6, 2018)
Bacteriocin for new application. Patent Application 2022/253743 A1 (filed 30 May 2022)
Cerein 7B bacteriocin for new application. Patent...
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
The Ultimate Scientific and Technical Reference